title: Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis.
abstract: METHODS
  The expression of p53 protein in 100 large bowel cancers was studied immunohistochemically by use of a monoclonal antibody (PAb1801).
  
  
  RESULTS
  Immunoreactivity was found in 61.0% of specimens from 100 patients with colorectal cancer. The pattern of p53 expression was mainly detected in the nuclei of the cancer cells. There was no significant correlation between the expression of p53 and the histologic grade, tumor size, serosal invasion, lymphatic invasion, venous invasion, lymph node metastasis, or liver metastasis. However, patients with p53-positive tumors had a greater relative risk of death compared with those with p53-negative tumors. The p53 negative-tumors showed a recurrence rate of 5.9%; for the p53 positive-tumors, a recurrence rate of 23.8% was recorded. The 3-year survival rate was 96.7% of 39 patients with p53-negative carcinomas and 61.8% for the patients with p53-positive tumors; there was a significant difference in the rate between the two groups of patients (P < 0.05). The growth fraction of p53-positive tumors determined with a monoclonal antibody against DNA polymerase alpha (49.0%) was significantly higher than that of p53-negative tumors (40.7%, P < 0.01).
  
  
  CONCLUSIONS
  These results suggest that the immunoreactivity of p53 may be a biologic marker of prognostic significance.
authors.affiliation: Department of Surgery II, School of Medicine, Kanazawa University, Ishikawa, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Yamaguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kurosaka
authors.forename: S
authors.initials: S
authors.lastname: Fushida
authors.forename: M
authors.initials: M
authors.lastname: Kanno
authors.forename: Y
authors.initials: Y
authors.lastname: Yonemura
authors.forename: K
authors.initials: K
authors.lastname: Miwa
authors.forename: I
authors.initials: I
authors.lastname: Miyazaki
mesh_terms: D000704:Analysis of Variance; D000911:Antibodies, Monoclonal; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000601:surgery; D004257:DNA Polymerase II / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000737:chemistry; D011379:Prognosis; D013997:Time Factors; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000276:immunology / Q000502:physiology
chemical_list: D000911:Antibodies, Monoclonal; D016159:Tumor Suppressor Protein p53; D004257:DNA Polymerase II